An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children.
Vaccine
; 36(5): 758-764, 2018 01 29.
Article
en En
| MEDLINE
| ID: mdl-29249543
ABSTRACT
BACKGROUND:
Influenza vaccination may provide a "back-boost" to antibodies against previously encountered strains. If the back-boost effect is common, this could allow more aggressive vaccine updates, as emerging variants would be expected to both elicit de-novo responses and boost pre-existing responses against recently circulating strains. Here we used the emergence of an antigenically novel A(H3N2) strain to determine whether an antigenically updated vaccine boosted antibodies against historical strains.METHODS:
We performed hemagglutination-inhibition (HI) assays on pre- and post-vaccination sera from 124 children 5-17â¯years old who received 2015-2016 inactivated influenza vaccine, containing an antigenically updated A(H3N2) strain. We evaluated the mean fold increase in HI titer against both the 2015-2016 vaccine strain and representative strains from two prior antigenic clusters. Factors associated with post-vaccination titers against historical strains were evaluated using linear regression, adjusting for baseline titer.RESULTS:
Geometric mean titers against each antigen examined increased significantly after vaccination (Pâ¯<â¯.0001). Mean fold increase was 3.29 against the vaccine strain and 1.22-1.46 against historical strains. Response to vaccine strain was associated with increased post-vaccination titers against historical strains.CONCLUSIONS:
A vaccine containing an antigenically novel A(H3N2) strain modestly boosted antibody responses against historical influenza strains in children.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Gripe Humana
/
Subtipo H3N2 del Virus de la Influenza A
/
Anticuerpos Antivirales
/
Antígenos Virales
Límite:
Adolescent
/
Child
/
Child, preschool
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Vaccine
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos